10x Genomics TXG
85.71
1.60
1.90%
as of 25 Sep
- Market cap
- $11.1B
- P/E
- 0.0×
Follow TXG
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(10.12%) | (5.78%) | (2.98%) | (9.40%) | |
| (7.77%) | (4.44%) | (2.36%) | (7.47%) | ||
ROIC |
(18.83%) | (13.97%) | (8.81%) | (20.20%) | |
Return on Tangible Assets |
(10.24%) | (5.75%) | (2.92%) | (9.74%) | |
Average Days of Receivables |
54.93 | 46.84 | 32.08 | 29.96 | |
Free Cash Flow per Share |
0.65 | 1.04 | 0.95 | 0.93 | |
Free Cash Flow |
81.65 | 130.12 | 122.18 | 121.44 | |
Capital Expenditures |
(6.87) | (5.93) | (5.64) | (5.65) | |
Piotroski F-Score |
4.00 | 5.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
6.99% | 10.31% | 9.44% | 9.23% | |
Accounts Receivable Turnover |
7.13 | 7.52 | 11.75 | 7.27 | |
Accounts Payable Turnover |
9.03 | 15.52 | 14.13 | 10.09 | |
Inventory Turnover |
2.56 | 2.85 | 3.03 | 3.04 | |
Average Days of Payables |
32.97 | 23.36 | 32.76 | 40.85 | |
Days of Inventory on Hand |
113.06 | 103.37 | 100.55 | 103.88 | |
Tax Rate |
0.04 | 0.09 | 0.18 | 0.00 | |
Research and Development Expense of Revenue |
38.89% | 37.12% | 36.20% | 36.76% | |
Selling, General and Administrative Expense of Revenue |
51.94% | 49.18% | 45.83% | 48.14% | |
Share Based Compensation of Revenue |
18.14% | 16.97% | 15.76% | 16.01% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.16) | (3.12) | (5.64) | (1.69) | |
Depreciation/Fixed assets |
0.17 | 0.19 | 0.21 | 0.22 | |
Capex/Depreciation |
(0.17) | (0.14) | (0.12) | (0.12) | |
Revenue per Share |
5.11 | 5.15 | 4.98 | 4.75 | |
Operating CF per Share |
0.71 | 1.09 | 1.00 | 0.98 | |
Capex per Share |
(0.05) | (0.05) | (0.04) | (0.04) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(11.89%) | (6.77%) | (3.55%) | (12.18%) |
Columns are period end dates